Last scanned
Domain Age
Daily Visitors
Global Rank
Updated:
Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye” | Novartis
Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline in ophthalmology Basel, April 20, 2020 — Novartis announced today that it has completed the acquisition of Amblyotech, a US-based software startup, and will, in collaboration with Ubisoft and McGill University, pursue the development of the acquired di...
This website is hosted with CloudFlare, Inc., which reserves the following IP addresses for amblyotech.com: 104.18.10.115, 104.18.11.115. Moreover, DNS used with this website include a1-254.akam.net, a2-66.akam.net, a24-65.akam.net, a28-67.akam.net, a7-64.akam.net, a9-65.akam.net, dns1.novartis.com, dns2.novartis.com, dns3.novartis.com, dns4.novartis.com. Subnet identifier ranges from 104.16.0.0 to 104.31.255.255. Classless Inter-Domain Routing (CIDR) is 104.16.0.0/12. ARIN net type is Direct Allocation.
Last scanned
Domain Age
Daily Visitors
Global Rank
CloudFlare, Inc.
a1-254.akam.net
a2-66.akam.net
a24-65.akam.net
a28-67.akam.net
a7-64.akam.net
a9-65.akam.net
dns1.novartis.com
dns2.novartis.com
dns3.novartis.com
dns4.novartis.com
{{value}}
2013-08-30
2024-08-30
MarkMonitor Inc.
{{value}}
The registrar of amblyotech.com is MarkMonitor Inc. and the name expires on 2024-08-30. According to open source data, you can reach the owner at jkoziak@msn.com but please make sure you have a good reason for unsolicited messages. Their country of residence is United States of America.
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A